Things began to happen with Chiroscience. Never mind, Chiroscience ended up getting a 20 million pay-off, and this was only the beginning of an exciting year. Celsis became one of the first biotech companies to go into profit, whilst Peptide lost its chairman, Alan Goodman, who resigned to be replaced by former Anglia Water chief, Alan Smith. In June, Babraham Institute heard it had planning permission from South Cambridgeshire District Council to expand. Gemini, announced research findings on twins showing it's not what you eat, but what you do that dictates your weight.
Exercise is key.
Peptide looked for runaway success with its travellers' tummy vaccine. Chiroscience and Celltech merged and everyone waited for a string of biotech marriages to follow in the wake of the new 700 million combined company. Roche backed Axis Genetics who made a major advance with human vaccine grown in potatoes, but sadly it was a swan song. The company went to the wall a few weeks later. August began with praise for Cantab Pharmaceuticals, one of the country's leading biotech companies, from Science Minister, Lord Sainsbury, who said the company was helping to make the UK a world leader in the sector.